Evidence map›Paper›PMID 34407634›Full record

ArticleArteriosclerosis, thrombosis, and vascular biology2021

Deletion of AT1a (Angiotensin II Type 1a) Receptor or Inhibition of Angiotensinogen Synthesis Attenuates Thoracic Aortopathies in Fibrillin1

Jeff Z Chen, Hisashi Sawada, Dien Ye, Yuriko Katsumata, Masayoshi Kukida, Satoko Ohno-Urabe, Jessica J Moorleghen, Michael K Franklin, Deborah A Howatt, Mary B Sheppard and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Arteriosclerosis, thrombosis, and vascular biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 28 citations in OpenAlex.

  1. Cautionary Data on Antihypertensives in Aortic Diseases.Hypertension (Dallas, Tex. : 1979) · 2026
    Article
  2. Review
  3. Angiotensin II Induces Abdominal Aortic Branch Aneurysms inArteriosclerosis, thrombosis, and vascular biology · 2026
    Article
  4. Growth arrest of thoracic aortic aneurysms in aging Marfan mice.American journal of physiology. Heart and circulatory physiology · 2026
    Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Angiotensinogen as a Therapeutic Target for Cardiovascular and Metabolic Diseases.Arteriosclerosis, thrombosis, and vascular biology · 2024
    Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 3 countries.

Jeff Z Chen *Saha Cardiovascular Research Center (J.Z.C., H.S., D.Y., M.K., S.O.-U., J.J.M., M.K.F., D.A.H., M.B.S., H.S.L., A.D.), University of Kentucky, Lexington.ORCID 0000-0002-2893-1523
Hisashi Sawada *Saha Cardiovascular Research Center (J.Z.C., H.S., D.Y., M.K., S.O.-U., J.J.M., M.K.F., D.A.H., M.B.S., H.S.L., A.D.), University of Kentucky, Lexington.ORCID 0000-0003-0017-6236
Dien YeSaha Cardiovascular Research Center (J.Z.C., H.S., D.Y., M.K., S.O.-U., J.J.M., M.K.F., D.A.H., M.B.S., H.S.L., A.D.), University of Kentucky, Lexington.ORCID 0000-0002-6433-5032
Yuriko KatsumataDepartment of Biostatistics (Y.K.), University of Kentucky, Lexington.
Masayoshi KukidaSaha Cardiovascular Research Center (J.Z.C., H.S., D.Y., M.K., S.O.-U., J.J.M., M.K.F., D.A.H., M.B.S., H.S.L., A.D.), University of Kentucky, Lexington.
Satoko Ohno-UrabeSaha Cardiovascular Research Center (J.Z.C., H.S., D.Y., M.K., S.O.-U., J.J.M., M.K.F., D.A.H., M.B.S., H.S.L., A.D.), University of Kentucky, Lexington.
Jessica J MoorleghenSaha Cardiovascular Research Center (J.Z.C., H.S., D.Y., M.K., S.O.-U., J.J.M., M.K.F., D.A.H., M.B.S., H.S.L., A.D.), University of Kentucky, Lexington.
Michael K FranklinSaha Cardiovascular Research Center (J.Z.C., H.S., D.Y., M.K., S.O.-U., J.J.M., M.K.F., D.A.H., M.B.S., H.S.L., A.D.), University of Kentucky, Lexington.
Deborah A HowattSaha Cardiovascular Research Center (J.Z.C., H.S., D.Y., M.K., S.O.-U., J.J.M., M.K.F., D.A.H., M.B.S., H.S.L., A.D.), University of Kentucky, Lexington.
Mary B SheppardSaha Cardiovascular Research Center (J.Z.C., H.S., D.Y., M.K., S.O.-U., J.J.M., M.K.F., D.A.H., M.B.S., H.S.L., A.D.), University of Kentucky, Lexington.
Adam E MullickIonis Pharmaceuticals, Carlsbad, CA (A.E.M.).
Hong S LuSaha Cardiovascular Research Center (J.Z.C., H.S., D.Y., M.K., S.O.-U., J.J.M., M.K.F., D.A.H., M.B.S., H.S.L., A.D.), University of Kentucky, Lexington.ORCID 0000-0002-0577-2558
Alan DaughertySaha Cardiovascular Research Center (J.Z.C., H.S., D.Y., M.K., S.O.-U., J.J.M., M.K.F., D.A.H., M.B.S., H.S.L., A.D.), University of Kentucky, Lexington.ORCID 0000-0003-2093-3775
University of Kentucky · USIonis Pharmaceuticals (United States) · US

Funding

Kentucky Center for Clinical and Translational ScienceUL1TR001998 · NCATS · UNIVERSITY OF KENTUCKY · PI HARTMANN, KATHERINE E, KERN, PHILIP A · 2016 to 2025
$34.2M
Adventitial-medial interactions in thoracic aortic diseasesR01HL133723 · NHLBI · UNIVERSITY OF KENTUCKY · PI DAUGHERTY, ALAN · 2016 to 2019
$2.9M
Pharmacological Mechanistic Insights into Thoracic Aortic AneurysmK01HL149984 · NHLBI · UNIVERSITY OF KENTUCKY · PI SHEPPARD, MARY BURCHETT · 2021 to 2025
$886k
Mechanisms of renin angiotensin modulation in thoracic aortic aneurysmsF30HL143943 · NHLBI · UNIVERSITY OF KENTUCKY · PI CHEN, JEFF ZHEYING · 2019 to 2021
$130k
NCATS NIH HHS UL1 TR001998NHLBI NIH HHS F30 HL143943NHLBI NIH HHS K01 HL149984NHLBI NIH HHS R01 HL133723
6 · The paper itself

Abstract

Objective: A cardinal feature of Marfan syndrome is thoracic aortic aneurysm. The contribution of the renin-angiotensin system via AT1aR (Ang II [angiotensin II] receptor type 1a) to thoracic aortic aneurysm progression remains controversial because the beneficial effects of angiotensin receptor blockers have been ascribed to off-target effects. This study used genetic and pharmacological modes of attenuating angiotensin receptor and ligand, respectively, to determine their roles on thoracic aortic aneurysm in mice with fibrillin-1 haploinsufficiency (Fbn1C1041G/+). Approach and Results: Thoracic aortic aneurysm in Fbn1C1041G/+ mice was found to be strikingly sexual dimorphic. Males displayed aortic dilation over 12 months while aortic dilation in Fbn1C1041G/+ females did not differ significantly from wild-type mice. To determine the role of AT1aR, Fbn1C1041G/+ mice that were either +/+ or -/- for AT1aR were generated. AT1aR deletion reduced expansion of ascending aorta and aortic root diameter from 1 to 12 months of age in males. Medial thickening and elastin fragmentation were attenuated. An antisense oligonucleotide against angiotensinogen was administered to male Fbn1C1041G/+ mice to determine the effects of Ang II depletion. Antisense oligonucleotide against angiotensinogen administration attenuated dilation of the ascending aorta and aortic root and reduced extracellular remodeling. Aortic transcriptome analyses identified potential targets by which inhibition of the renin-angiotensin system reduced aortic dilation in Fbn1C1041G/+ mice. Conclusions: Deletion of AT1aR or inhibition of Ang II production exerted similar effects in attenuating pathologies in the proximal thoracic aorta of male Fbn1C1041G/+ mice. Inhibition of the renin-angiotensin system attenuated dysregulation of genes within the aorta related to pathology of Fbn1C1041G/+ mice.

Indexed as

Gene DeletionRenin-Angiotensin SystemAdipokinesAngiotensinogenAnimalsAorta, ThoracicAortic Aneurysm, ThoracicDisease Models, AnimalFemaleFibrillin-1Genetic Predisposition to DiseaseHaploinsufficiencyMaleMarfan SyndromeMiceMice, Inbred C57BLAdipokinesAgt protein, mouseAgtr1a protein, mouseAngiotensinogenFbn1 protein, mouseFibrillin-1Oligonucleotides, AntisenseReceptor, Angiotensin, Type 1angiotensin IIangiotensinogenaortic aneurysmMarfan syndromerenin-angiotensin system

Identifiers

PMID34407634
PMCPMC8458261
OpenAlexW3194828011

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.